EUVIMEDEUVIMED entdecken
Crossref

Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis

Garth W Strohbehn iD, Molly C Tokaz iD, Daniel Sanghoon Shin iD, Shadia Jalal, Hannah F Tavalire iD, Derek J Gyori iD, Julie A Moeller iD, Brian G Bazzell iD, Michael J Kelley iD, A Mark Fendrick iD, David A Elliott, Nithya Ramnath und 2 weitere

JCO Oncology Practice · 18.06.2026

DOI: 10.1200/op-25-01241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 18.06.2026. Verfasst von Garth W Strohbehn und 13 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI. Die Arbeit nennt 43 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pemetrexed remains part of guideline-recommended maintenance pemetrexed/pembrolizumab in advanced/metastatic non–oncogene-driven nonsquamous non–small cell lung cancer (NSCLC). Whether pemetrexed contributes to the combination's survival benefit is unknown. In this propensity-weighted analysis of US Veterans Affairs data, we compared real-world effectiveness and safety of maintenance pemetrexed/pembrolizumab versus maintenance pembrolizumab alone and estimated US government payer spending on maintenance pemetrexed. METHODS We identified Veterans who received four cycles of carboplatin/cisplatin, pemetrexed, and pembrolizumab followed by at least one dose of maintenance pemetrexed/pembrolizumab or pembrolizumab. A propensity-weighted Cox model was used to adjust for baseline between-group differences using inverse probability of treatment weights. The primary effectiveness outcome was overall survival (OS; time from first maintenance dose to death). The primary financial outcome was the estimated spending on maintenance pemetrexed across VA, Medicare Part B, and Medicaid (2017-2022). RESULTS The real-world outcomes cohort included 622 patients (473 pemetrexed/pembrolizumab; 149 pembrolizumab alone). After propensity weighting, pemetrexed was not associated with improved OS (adjusted hazard ratio [aHR] pemetrexed/pembrolizumab v pembrolizumab, 1.06 [95% CI, 0.83 to 1.36, P = .62]) but was associated with higher toxicity risk (grade ≥3 acute kidney injury [aHR 3.35, 95% CI, 1.08 to 10.41, P = .04]; neutropenia [aHR 2.86, 95% CI, 1.44 to 3.05; P = .004]; anemia [aHR 1.65, 95% CI, 1.11 to 2.47, P = .014]). Findings were robust to sensitivity analysis in which patients who crossed over from pembrolizumab to pemetrexed/pembrolizumab were excluded. Estimated government payer spending on maintenance pemetrexed from 2017 to 2022 totaled $1.588 billion (2024 USD). CONCLUSION Adding pemetrexed to maintenance pembrolizumab was not associated with improved survival but was associated with increased toxicity. Reassessing legacy chemotherapy components may improve the safety and cost-effectiveness of cancer care . Prospective evaluation of maintenance pemetrexed's incremental benefit in NSCLC in the immunotherapy era is needed.

Autor:innen und Institutionen

  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI.
  • Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI.
  • Division of Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, MI.
  • Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI.
  • Lung Precision Oncology Program, Charles S. Kettles VA Medical Center, Ann Arbor, MI.
  • Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.

ORCID-Profile: Garth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, Hannah F Tavalire, Derek J Gyori, Julie A Moeller, Brian G Bazzell, Michael J Kelley, A Mark Fendrick, Timothy P Hofer, Alex K Bryant

Zitieren

APA

Strohbehn, G. W., Tokaz, M. C., Shin, D. S., Jalal, S., Tavalire, H. F., Gyori, D. J., Moeller, J. A., Bazzell, B. G., Kelley, M. J., Fendrick, A. M., Elliott, D. A., Ramnath, N., Hofer, T. P., & Bryant, A. K. (2026). Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis. JCO Oncology Practice. https://doi.org/10.1200/op-25-01241

Vancouver

Strohbehn GW, Tokaz MC, Shin DS, Jalal S, Tavalire HF, Gyori DJ, et al. Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis. JCO Oncology Practice. 2026. doi:10.1200/op-25-01241

BibTeX
@article{Strohbehn2026,
  author = {Strohbehn, Garth W and Tokaz, Molly C and Shin, Daniel Sanghoon and Jalal, Shadia and Tavalire, Hannah F and Gyori, Derek J and Moeller, Julie A and Bazzell, Brian G and Kelley, Michael J and Fendrick, A Mark and Elliott, David A and Ramnath, Nithya and Hofer, Timothy P and Bryant, Alex K},
  title = {Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-01241}
}
Kostenlos starten →